Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

How Long Can a Human Survive Without Food and Water?

How Long Can a Human Survive Without Food and Water?
In this article

The commonly circulated answer to the question "How long can a human survive without food and water?" is simple: three days without water, one or two months without food. The reality is far more variable — and records are not the main subject of this article. In a cancer patient, loss of appetite, wasting and stopping drinking water in the final days of life are explained not by the limits of survival, but by an entirely different physiology. Confusing the two leads to one of the most distressing misunderstandings experienced by patients' families.

The first half of this article describes the physiology and documented cases with corrected figures. The second half concerns oncology directly: why cancer cachexia differs from simple starvation, what refeeding syndrome is, and what the evidence says about what intravenous fluids do — and do not do — for a patient in the final days of life.

A warning at the outset. The timeframes in this article describe the limits of survival; they are not targets. Prolonged fasting without medical supervision carries a risk of serious and sometimes irreversible harm. If you are struggling with eating or are worried about your weight, do not use the figures in this article as a benchmark; consult a physician or someone you trust — support is available and effective.

Five corrections first

Common statements and their verified counterparts
Circulating statement The correction
"Hunger strikes generally ended in death after 45–61 days" The range is too narrow. The durations for the ten people who died in the 1981 Maze Prison hunger strike ranged from 46 to 73 days. The shortest was Martin Hurson (46 days), and the longest was Kieran Doherty (73 days). The strikers were taking water and salt. Much shorter durations, such as 28, 36, 38 and 40 days, have also been reported in the literature.
"Andreas Mihavecz went without food and water for 18 days" The duration and year are correct (he was forgotten in a holding cell in Bregenz, Austria, on 1–19 April 1979), but he was not completely without water: he survived by licking condensation from the cell walls. He lost 24 kilograms. This is therefore a case of "minimal water," not "no water."
"Angus Barbieri fasted for 382 days in 1965" The duration is correct, but the date is incomplete: the fast ran from 14 June 1965 to 30 June 1966. Nor did he drink only water — he consumed tea, coffee, mineral water, vitamins, potassium and sodium supplements, and yeast extract. His weight fell from 207 kg to 82 kg. He was under medical supervision in Dundee; it was published in the Postgraduate Medical Journal in 1973.
"Symptoms of dehydration include fever and cerebral edema " Incorrect — and an important error. Cerebral edema is not a symptom of dehydration; it is a complication of correcting hypernatremic dehydration too rapidly. During dehydration, brain cells shrink, rather than swell. For this reason, serum osmolality is not reduced faster than 0.5 mOsm/L per hour in severe cases.
"Electrolyte disturbances (e.g., thiamine/K⁺)" Thiamine is a vitamin (B1), not an electrolyte. It is nevertheless a genuine part of starvation and refeeding — but alongside, rather than among, the electrolyte shifts. Its deficiency causes Wernicke-Korsakoff syndrome.

Where does the "three days" rule come from?

Three days without water, three weeks without food, three hours without shelter, three minutes without air — in the survival literature, this is called the "rule of threes". It is memorable, but it does not originate from a scientific study; it is a rule of thumb and is not scientifically exact.

Temperature is the main variable determining survival without water. As temperature rises, water loss increases and the time shortens; in extreme heat, death can occur not within days but within hours from heatstroke. In a cool environment, the time is considerably longer. Rather than giving a single figure, it is therefore more accurate to say: survival without water may be less than one day in extreme heat and may exceed two weeks in sheltered, cool conditions. The determinants are ambient temperature, humidity, physical activity, initial hydration and body size.

In bedridden, immobile people — that is, patients nearing the end of life — when both food and water intake cease, death has typically been reported to occur within 10–14 days, within an approximate range of one to three weeks. This figure describes a situation entirely different from that of someone walking in the heat, and the two cannot be used interchangeably.

How much of the body is water? What does each percentage measure?

The statement "The body is 60% water" is correct for an average adult man, but it is not universal.

Total body water as a proportion of body weight
Group Proportion
Newborn 70–78%
One-year-old infant ~65%
Adult man ~60%
Adult woman ~55%
Obese adult 40% or less

The difference arises because fat tissue contains much less water than muscle tissue. The same amount of fluid loss therefore produces conditions of different severity in different people.

A common mistake arises here: "3% loss" and "10% loss" use different denominators. As a percentage of total body water: 3–4% reduction is tolerated by most people without difficulty; 5–8% causes fatigue and dizziness; more than 10% is associated with physical and mental impairment and intense thirst; 15–25% is fatal. The pediatric classification used clinically, however, considers a percentage of body weight and gives entirely different thresholds. When reading a percentage, one must ask "a percentage of what?"

Clinical classification of dehydration (as a percentage loss of body weight)
Severity Infants Older children and adolescents
Mild 5% 3%
Moderate 10% 5–6%
Severe 15% 7–9%

Severe dehydration accompanied by signs of circulatory impairment requires urgent intravenous fluid replacement.

What does the body do during starvation? The sequence of fuel switching

When food intake stops, the body does not act randomly; it switches fuels in a specific sequence, which determines which tissue is used up and when.

Stages of starvation while water intake continues
Period Main fuel What happens?
0–24 hours Glycogen Glycogen stores in the liver and muscle are converted to glucose to maintain blood sugar. Weakness, irritability and intense hunger.
From day 2 onward Fat Fat mobilization accelerates and ketone bodies increase — ketosis. The brain gradually switches to using ketones. Hunger may paradoxically decrease; metabolism slows.
First days — Rapid weight loss occurs, but much of it is water; each gram of glycogen holds several grams of water alongside it.
Weeks Fat + protein As fat stores diminish, muscle proteins are broken down and converted to energy. Muscle wasting, weakening of immunity and infection risk.
Advanced stage Protein Risk of electrolyte disturbances, cardiac arrhythmias and multiple organ failure. Death is generally due to loss of heart muscle and arrhythmia, rather than directly to "running out of energy."

This sequence explains why starvation is tolerated so much longer than dehydration. Fat tissue is a dense energy store, and the body tries to preserve muscle as much as possible while using it — slowing metabolism, switching to ketones and suppressing protein breakdown. Water has no such store. Water loss directly reduces blood volume and impairs circulation; there is no intermediate solution. The body can borrow energy, but not volume.

Documented cases: the figures

Documented extreme cases of starvation and dehydration
Case Duration Conditions Note
Angus Barbieri
1965–66, Scotland
382 days No solid food; tea, coffee, mineral water, vitamins, potassium and sodium supplements. Under medical supervision. 207 kg → 82 kg. Postgraduate Medical Journal, 1973. Must never be attempted outside clinical supervision.
Poon Lim
1942–43, Atlantic
133 days SS Benlomond was torpedoed (23 November 1942); he was rescued off Brazil on 5 April 1943. The raft's 45 liters of water and provisions ran out around day 70. He subsequently collected rainwater and caught fish and seabirds.
Maze Prison hunger strike
1981, Northern Ireland
46–73 days No solid food, while water and salt intake continued. Ten people died. The shortest duration was 46 days, and the longest was 73 days. This range is the best human evidence we have for an "upper limit of starvation."
Andreas Mihavecz
1979, Austria
18 days Forgotten in a holding cell; no food, and condensation on the wall instead of water. He lost 24 kilograms. Often cited as a "record for survival without water" — the Guinness entry could not be verified for this article.
Minnesota Starvation Experiment
1944–45, USA
24 weeks 36 volunteers; 12 weeks of control at ~3,200 kcal, 24 weeks of ~1,560 kcal semistarvation, followed by two-stage rehabilitation. The target was to lose ~25% of initial body weight. Findings are discussed later.

The most lasting outcome of the Minnesota experiment is psychological, rather than physiological. During semistarvation, participants developed substantial increases in measures of depression, hysteria and hypochondriasis, obsessive preoccupation with food, a substantial loss of sexual interest and social withdrawal. The rehabilitation period was also psychologically difficult. The two-volume work published by Ancel Keys and his team in 1950, The Biology of Human Starvation, remains a foundational source for understanding eating disorders today. Its counterpart in oncology is this: being unable to eat enough is not only a nutritional problem, but also a mood problem — and a patient's "not wanting to eat" is sometimes part of this cycle. We discussed the overlap between fatigue and low mood in cancer in our article on weakness and fatigue.

Under the rubble: evidence with direct relevance to Turkey

How long can someone trapped under earthquake rubble survive? Our strongest source for this question is an analysis covering 1985–2004 and examining 34 earthquakes, compiling rescue times from 48 medical publications (Prehospital and Disaster Medicine, 2006).

Survival under rubble — compiled data
Longest reliable report 14 days; the closest case was 13 days
Second-longest well-documented case in the medical literature 8.7 days (209 hours)
Number of articles reporting rescue after 48 hours 25
Mean maximum duration in 18 earthquakes with rescues after the second day 6.8 days (median 5.75 days)
1999 Marmara earthquake Documented rescue times for 43 people 0.5 – 6.2 days

The "golden 72 hours" is a planning rule, not a biological limit. Most rescues occur within the first 24 hours — but the data above show numerous live rescues after 48 hours and a few cases reaching 13–14 days. There is no medical basis for scaling back search-and-rescue efforts at the end of the third day.

Crush syndrome: the silent threat beneath rubble

The main danger under rubble is often not dehydration. Muscle tissue under prolonged pressure breaks down (rhabdomyolysis) and its cellular contents enter the circulation. In the American College of Emergency Physicians' definition, crush syndrome is "a local crush injury with systemic manifestations."

Components of crush syndrome
Component What happens?
Fluid sequestration Within 48 hours, the crushed region may receive more than 12 liters of leaked fluid → hypovolemia and shock
Hyperkalemia Potassium from ischemic muscle enters the circulation → cardiac arrhythmia
Hypocalcemia Calcium leaks into damaged muscle cells
Metabolic acidosis Lactic acid accumulation
Myoglobinuria → kidney failure Approximately 50% of patients with crush syndrome develop acute kidney failure
Compartment syndrome Muscle swelling increases pressure; fasciotomy may be necessary

Crush injuries from building collapse in earthquakes occur in 3–20% of injured people and affect the legs in 74% of cases.

The one-sentence rule of emergency management: "Give intravenous fluids before freeing the crushed limb." This is particularly critical when crushing has lasted more than four hours, because potassium and myoglobin flood into the circulation as soon as pressure is released. In hospital, fluid treatment continues at up to 1.5 liters per hour. Early, aggressive fluid treatment should ideally start before extraction from the rubble. Thus, telling someone to "give water" to the person trapped under rubble is not enough; intravenous access is needed.

Starvation in a cancer patient is different: cachexia

Everything described so far concerns simple starvation: there is no food, the body uses its stores and recovers when food is given. The wasting seen in cancer patients does not follow this logic — and this is the most important sentence in the article.

According to the international consensus definition, cancer cachexia is "a multifactorial syndrome defined by ongoing loss of skeletal muscle mass (with or without fat loss), which cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment."

The National Cancer Institute states this even more explicitly: "Increasing calorie intake, whether orally or through total parenteral nutrition, has failed to stop the wasting process" and "energy deficit alone does not explain the pathogenesis of cachexia." The wording on its patient information page is clearest: "It can occur even when eating well."

Diagnostic criteria for cancer cachexia (any one of the three)
Involuntary weight loss More than 5% in 6 months
BMI below 20 kg/m² and weight loss of more than 2%
Sarcopenia and weight loss of more than 2%
The three stages of cachexia
Stage Definition Opportunity for intervention
Precachexia Early metabolic signs before marked weight loss; mild weight loss and appetite problems Early treatment at this stage may slow progression
Cachexia Muscle loss meeting the above criteria, difficult to reverse and affecting daily functioning Limited
Refractory cachexia Severe weight and muscle loss, unresponsive to treatment; advanced disease, life expectancy of less than three months The goal is now comfort, rather than weight
33–52%frequency of cachexia in cancer patients
Up to 80%in terminally ill patients
22–40%share of cancer deaths attributed to cachexia
50%frequency of sarcopenia in advanced cancer (NCI)

The highest rates occur in upper gastrointestinal, colorectal and lung cancers. Detailed percentages by tumor type could not be verified for this article. Pancreatic cancer, stomach cancer and esophageal cancer also involve a mechanical problem: the patient cannot eat because the passage is obstructed. These two conditions must be distinguished — one improves with nutritional support, the other does not.

The difference between simple starvation and cancer cachexia
Simple starvation Cancer cachexia
Tissue lost Primarily fat; the body tries to preserve muscle Primarily skeletal muscle; fat loss may or may not accompany it
Metabolism Slows down — switches to conservation mode Does not slow down; inflammation and metabolic disruption continue
When food is given Reverses Does not fully reverse
When the patient eats well Wasting does not occur Wasting may continue
Underlying problem Energy deficit Energy deficit is not the problem — or not the only one

In practice, this situation translates into the conflict most commonly experienced by patients' families. The family attributes weight loss to inadequate nutrition and pressures the patient to eat. The patient cannot eat, and even when they do, they do not gain weight. The family feels guilty, the patient feels pressured, and the dinner table becomes a battleground again every day. Yet the problem is neither the family's lack of care nor the patient's stubbornness — it is the metabolic state created by the tumor. Explaining this clearly is often the best supportive care that can be offered. Changes in taste and other factors further reduce appetite, and some of these can indeed be corrected.

Can cachexia be treated?

The short answer: not fully, but the field is moving. Looking at three drugs is sufficient.

Megestrol acetate — old and misleading

The evidence for megestrol acetate in cachexia
Increased appetite In approximately one in four patients
Weight gain In approximately one in twelve patients
Nature of the weight gained "Largely fat tissue, not muscle"
Survival No study has demonstrated a survival advantage
Quality of life No clear benefit has been demonstrated
Important risks Thromboembolic events; suppression of the hypothalamic-pituitary-adrenal axis causing adrenal insufficiency
Dose 160–800 mg/day orally; no additional benefit above 800 mg

Megestrol is a textbook example of "choosing the right endpoint" in oncology. The drug increases weight — but the added weight is fat. Yet the definition of cachexia is muscle loss. In other words, the drug improves an easily measured surrogate, rather than the measure of the disease. The number on the scale rises, but the patient's ability to climb stairs does not change. Weight is the wrong endpoint in cachexia — and this criticism should also be kept in mind for the new drugs below.

Anamorelin — approved in Japan, rejected in Europe

Anamorelin is an oral selective ghrelin receptor agonist; it aims to increase appetite by stimulating the receptor for the hunger hormone. Two major markets reached opposite decisions.

Anamorelin's regulatory history
Authority Decision Details
Japan Approved 22 January 2021 approval, 21 April 2021 market launch. Trade name: Adlumiz. Indication: cachexia in non-small cell lung cancer, stomach cancer, pancreatic cancer and colorectal cancer. Dose: 100 mg once daily on an empty stomach.
Europe (EMA) Rejected 18 May 2017recommendation for refusal; 14 September 2017refusal confirmed after reexamination. Reason: "a marginal effect on lean body mass, with no demonstrated effect on handgrip strength or quality of life" and inadequate recording of safety data.

The regulatory status in the USA and the numerical results of the ROMANA 1–2 studies could not be verified for this article.

The EMA's reason for refusal is precisely the criticism of megestrol described above. The drug slightly increases lean body mass, but handgrip strength — something that would actually help the patient — does not change. Opposite decisions by two authorities reviewing the same data show a lack of consensus on how "success" in cachexia should be defined. Differences in approvals between countries — discussed in our article — now have a third example.

Ponsegromab — the most promising new evidence in the field

Ponsegromab is a monoclonal antibody targeting a protein called GDF-15. GDF-15 is a molecule secreted by tumors that sends a "stop eating" signal to appetite centers in the brain; blocking it means intervening directly in the mechanism of cachexia.

Ponsegromab phase 2 trial (NCT05546476) — weight gain versus placebo at week 12
Dose (subcutaneous, every 4 weeks) Weight gain versus placebo 95% confidence interval Significant?
100 mg 2.02% −0.97 – 5.01 No (the interval includes zero)
200 mg 3.48% 0.54 – 6.42 Yes
400 mg 5.61% 2.56 – 8.67 Yes

187 patients with non-small cell lung, pancreatic or colorectal cancer and elevated GDF-15. Results were announced on 14 September 2024 and simultaneously published in the New England Journal of Medicine. Treatment-related adverse events occurred in 7.7% of the ponsegromab arm and 8.9% of the placebo arm.

Ponsegromab differs from megestrol in that it did not look only at weight. In the 400 mg arm, appetite and cachexia symptom measures, digitally measured physical activity and lumbar skeletal muscle index also improved. In other words, the scale, muscle and function all moved in the same direction — an unusual result in cachexia.

But the limitations are also clear: this is a phase 2 trial, lasting 12 weeks, the primary endpoint is still weight, and there are no survival data. Patients were selected for elevated GDF-15 — so the findings cannot be generalized to patients without an elevated level of this marker. The confidence interval for the lowest dose includes zero. Registration trials were planned to begin in 2025. As of today, ponsegromab is not approved in any country and telling patients that "a new cachexia drug is available" would be misleading.

Refeeding syndrome: starvation's most dangerous moment comes afterward

Counterintuitively, giving food to someone who has been starving for a long time can be dangerous. This is called refeeding syndrome, defined as medical complications arising from fluid and electrolyte shifts when a malnourished patient is aggressively refed.

Mechanism: When carbohydrates are given, blood glucose rises, triggering an insulin surge. Insulin drives phosphorus, potassium and magnesium into cells — partly through glucose phosphorylation and partly through stimulation of the sodium-potassium pump. Blood levels of these three elements fall rapidly. Fluid retention begins at the same time. Stores of thiamine (vitamin B1), already depleted during starvation, are rapidly consumed as glucose metabolism accelerates; deficiency causes Wernicke-Korsakoff syndrome.

The characteristic finding is hypophosphatemia. Hypokalemia and hypomagnesemia also occur, but low phosphate is the hallmark of refeeding syndrome. We discussed in detail why phosphate is so critical and what its deficiency causes — from muscle weakness to arrhythmia, osteomalacia and fractures — in our article on intravenous iron and hypophosphatemia. The same electrolyte becomes dangerous for the same reason in two entirely different clinical scenarios: because nobody checks it.

According to the ASPEN diagnostic criteria, complications arise within the first five days after calories are reintroduced. Those at risk include people with eating disorders, chronic alcohol use, kidney failure, malabsorption, previous bariatric surgery or depression — and anyone who has experienced prolonged starvation.

Patients at high risk of refeeding problems according to NICE criteria
One or more of the following OR two or more of the following
BMI below 16 kg/m² BMI below 18.5 kg/m²
Unintentional weight loss of more than 15% in the last 3–6 months Unintentional weight loss of more than 10% in the last 3–6 months
More than 10 days with little or no nutritional intake More than 5 days with little or no nutritional intake
Low potassium, phosphate or magnesium before feeding History of alcohol misuse; or use of insulin, chemotherapy, antacids or diuretics

Note: the last row in the right-hand column explicitly lists chemotherapy. Cancer patients are therefore a defined risk group for refeeding syndrome.

NICE's management recommendation is exactly counterintuitive: start slowly. Nutritional support starts at no more than 10 kcal/kg/day and gradually increases to full requirements over 4–7 days; in extreme cases (BMI below 14 kg/m² or virtually no intake for more than 15 days), 5 kcal/kg/day. Immediately before feeding and for the first 10 days, 200–300 mg of oral thiamine daily and a vitamin B complex are given. Potassium, phosphate and magnesium are supplemented concurrently. Telling a starving patient to "eat a little to get stronger" is well-intentioned but dangerous advice — refeeding is a procedure that must be planned under medical supervision.

Nutrition and fluids in the final days of life

This is the most difficult and most needed section of the article. The question is: what should be done when a patient in their final days of life stops eating and drinking? Do intravenous fluids help?

Our best evidence: a randomized trial

Parenteral hydration in patients with advanced cancer — a multicenter, double-blind, placebo-controlled randomized trial (Bruera et al.)
Number of patients 129 (the target was 150; stopped early because of funding), 6 hospice centers
Intervention arm Daily, 1 liter of normal saline, subcutaneously, over 4 hours
Control arm Daily, 100 mL of normal saline, over the same duration
Primary endpoint On day 4, change in the composite score for four dehydration-related symptoms (fatigue, myoclonus, sedation, hallucinations)
Result −3.3 versus −2.8; p = 0.77. No difference on days 4 and 7.
Secondary endpoints No difference in individual symptoms, delirium, quality of life or median survival

A difference in nighttime delirium favoring hydration was reported; however, because 47 secondary endpoints were tested, it is highly likely to have occurred by chance. The publication year is given differently as 2012 and 2013 in the sources; no year is specified in this article.

The result of this trial in one sentence: one liter of fluid daily did not improve patients' symptoms or prolong their lives. This does not mean "do not give fluids" — the trial compared 1 liter with 100 mL, rather than no fluids. But it establishes that: the assumption that intravenous fluids bring relief to patients in their final days has not been proven.

What do the guidelines say?

NICE's guideline on caring for adults in their final days of life explicitly states two recommendations:

  • "Support the dying person to drink if they wish to and are able to. Check for difficulties such as swallowing problems or a risk of aspiration."
  • "Offer the dying person frequent mouth and lip care and, if needed, include management of dry mouth in the care plan."

The quality standard requires that: "Adults in their final days of life have their hydration assessed daily and the benefits and risks of hydration options discussed." The rationale works in both directions: "Inadequate hydration can cause distressing symptoms such as thirst and delirium"; conversely, excessive artificial hydration carries a risk of aspiration and breathing difficulties.

We need to be honest here: there is no certainty on this issue. On one hand, the randomized trial shows that giving fluids did not improve symptoms; on the other, guidelines acknowledge that inadequate hydration may cause thirst and delirium. In the words of palliative care organizations, there is "no clear evidence that subcutaneous fluids at the end of life prolong life or improve quality of life" and it is "rarely appropriate to initiate artificial nutrition and hydration in the last few days". The right approach is not a rule, but an individual decision reassessed every day and discussed with the family. This article does not offer a one-sided recommendation.

"Are they dying of hunger?" — the question families ask most often

Contrary to what is often assumed, the answer to this question is clear: stopping eating is a consequence, not a cause, of dying. The patient is not dying because they are not eating; they are not eating because they are dying.

Palliative care sources state: "When a person is dying, how much they eat and drink does not change how long they will live." For patients who do not want to eat in their final days: "They do not feel hungry, and food and drink may cause them discomfort." The National Cancer Institute puts the same point this way: "People at the end of life often do not feel very hungry and may want very little food. Sips of water, ice chips and mouth care may help with the sensation of thirst."

And the most important sentence: "A person at the end of life should not be forced to eat or drink. Doing so may cause discomfort or choking."

What can be done for dry mouth
Method Note
Frequent mouth and lip care An explicit guideline recommendation; should be included in the care plan
Saliva substitute sprays and gels In consultation with a physician or pharmacist
Moisturizing the lips Petroleum jelly or a water-based gel
Small ice chips or frozen fruit juice May feel refreshing in the mouth
Small amounts of fluid using a needleless syringe or dropper Only if the person can swallow
Foam-tipped oral swabs Caution: Safety concerns have been reported that the foam tip could detach and cause choking

Dehydration during active treatment

There is a much more common and much more easily resolved problem than end-of-life issues: fluid loss during chemotherapy. In the words of the National Cancer Institute, "When you vomit, you may become dehydrated and lose large amounts of electrolytes."

Vomiting

Loss of both fluid and electrolytes. If nausea is not controlled, the treatment team should be informed — this is not a side effect that must simply be endured.

Diarrhea

The fastest route of fluid loss with some treatments. We discussed how to manage diarrhea in our article on loperamide.

Mouth sores

Mucositis prevents both eating and drinking because of pain, creating a vicious cycle.

Taste changes

Even water tasting unpleasant reduces fluid intake. A metallic taste is its best-known form.

Fever

Increases fluid requirements. Fever in a neutropenic patient is also an emergency.

Inadequate intake

Forgetting to drink because of poor appetite and fatigue is far more common than is generally assumed.

The treatment team should be contacted in the following situations: inability to retain fluids orally, markedly reduced or darker urine, dizziness on standing, a rapid heartbeat, unusual drowsiness or confusion, fever. This list is based on general clinical practice; a list of "warning signs" verified against a single authoritative guideline source could not be obtained for this article. The contact instructions provided by your own treatment center take priority.

DROZDOGAN Academy Commentary

The title of this article poses a question of curiosity, but its content concerns a clinical problem. The reason for keeping both in the same text is this: patients' families confuse these two questions — and when they do, they reach a harmful conclusion, such as pressuring their loved one to eat.

⚡ Why it matters

Because the intuition that "they will die if they do not eat" is powerful and wrong in advanced cancer. According to the international consensus definition, cachexia is a syndrome that cannot be fully reversed by conventional nutritional support; in the NCI's words, "it can occur even when eating well". Explaining this clearly to the family is often the most effective supportive care available — because it frees both the patient from pressure at mealtimes and the family from guilt.

✅ The strong point

We have better evidence in this field than is often assumed. The effect of parenteral hydration in the final days of life has been tested in a double-blind, placebo-controlled randomized trial — a design that is rare and ethically challenging in palliative care. For refeeding syndrome, clearly defined risk criteria and dose limits are available. The definition and staging of cachexia are based on international consensus. The uncertainty thus stems not from a lack of data, but from the complexity of the problem itself.

⚠️ The weak point

We have been making the same mistake in treating cachexia for forty years: measuring the wrong endpoint. Megestrol increases weight, but the additional weight is fat; anamorelin increases lean mass without changing handgrip strength — precisely why the EMA refused authorization. Ponsegromab's phase 2 data seem to break this pattern (muscle index and physical activity also improved), but the primary endpoint remains weight, the duration is 12 weeks, there are no survival data and it is not approved in any country. For end-of-life hydration, the randomized evidence and guideline statements do not fully align; this tension should be conveyed honestly, rather than turned into a one-sided recommendation.

🩺 Practical implications

(1) When assessing weight loss, ask not only "how much" but also "from which tissue"; muscle loss and fat loss are not the same. (2) Cachexia should be diagnosed early — precachexia is the stage when intervention has the greatest chance of helping. (3) In a patient with prolonged inadequate nutrition, refeeding starts at 10 kcal/kg/day, with phosphate, potassium and magnesium monitored and thiamine given. (4) Mechanical barriers (obstruction, mucositis, swallowing difficulties) should be distinguished from metabolic cachexia; the former can be resolved. (5) In the final days of life, the hydration decision should be reassessed daily and discussed with the family; mouth care should be provided in all circumstances. (6) Telling the family "do not force them to eat" is not enough; why they should not be pressured must be explained.

❓ Open questions

Blocking GDF-15 improves weight and muscle mass — but does it change survival and the patient's daily functioning? Without phase 3 data, this question remains unanswered. Second: if cachexia is identified early and exercise, nutrition and medication are combined, does the outcome change — or is the problem already the tumor itself? Third, and clinically most controversial: can we identify in advance who will benefit from fluids in the final days of life? Today, we have no criterion for making this distinction; the decision is made anew, individually, for each patient.

Conclusion: The answer to "How long can a human survive without food?" — weeks with water, days without it — tells us very little about a cancer patient. Wasting in cancer is caused not by stores running out, but by metabolism being rewritten; it therefore does not resolve when the plate is filled. The two most useful things to do clinically are to recognize cachexia early and, in the final days, avoid pressuring the patient. And perhaps most importantly: to be able to tell a patient's relative, clearly, with sources and with certainty, "your loved one is not dying of hunger." That sentence lifts a burden that no medication can remove.

Frequently asked questions

What is the longest a human can live without water?
It is not accurate to give a single figure. "Three days" is a common rule of thumb, but it is not scientifically exact. In extreme heat, the time may be less than one day — heatstroke causes death before dehydration does. There are documented cases exceeding two weeks in cool, sheltered, immobile conditions (Mihavecz, 18 days — but drinking condensation from the wall). The determinants are temperature, humidity, activity, initial hydration and body size.
How long can someone go without food while drinking water?
The best human evidence comes from hunger strikes: the ten people who died in the 1981 Maze Prison strike survived for 46 to 73 days (while taking water and salt). Much shorter durations, such as 28–40 days, have also been reported. The time varies greatly with initial fat stores, body size and accompanying illnesses.
Why does dehydration kill much faster than starvation?
Because water has no storage reserve. The body can borrow energy from fat, but cannot borrow blood volume from anywhere. Water loss directly impairs circulation, lowers blood pressure and prevents blood from reaching the organs. During starvation, metabolism slows, the body switches to ketones and muscle is preserved as much as possible.
Why does a cancer patient lose weight despite eating well?
This is called cancer cachexia. According to the international definition, it is a multifactorial syndrome involving skeletal muscle loss that cannot be fully reversed by conventional nutritional support. In the NCI's words, "it can occur even when eating well". The problem is therefore not insufficient food, but the metabolic state created by the tumor. Nevertheless, correctable causes of poor appetite (nausea, mouth sores, taste changes, obstruction, pain) must be sought.
Is there a drug for cachexia?
There is no approved drug specifically for cachexia in Turkey or Europe. Megestrol acetate increases appetite in one quarter of patients, but the weight gained is largely fat, and no survival advantage has been shown. Anamorelin was approved in Japan in 2021, but the European Medicines Agency rejected it in 2017. A new antibody called ponsegromab produced promising phase 2 results, but is not yet approved in any country.
Is it right to give food immediately to someone who has been starving for a long time?
No — this can be dangerous. Refeeding syndrome occurs when an insulin surge during refeeding drives phosphorus, potassium and magnesium into cells; its characteristic finding is hypophosphatemia, and complications occur within the first five days. In at-risk patients, NICE recommends starting nutrition at no more than 10 kcal/kg/day and giving thiamine. Refeeding requires medical supervision.
Should my dying patient receive intravenous fluids?
This decision must be made individually for each patient, and this article does not offer a one-sided recommendation. A randomized trial found that 1 liter of subcutaneous fluid daily did not improve symptoms or prolong survival. Guidelines, however, state that inadequate hydration may cause thirst and delirium, while excessive hydration carries a risk of aspiration and breathing difficulties, and call for daily assessment of hydration. Discuss the decision with the treatment team.
Is my loved one dying of hunger?
No. Stopping eating is a consequence, not a cause, of dying. In the words of palliative care sources, "when a person is dying, how much they eat and drink does not change how long they will live" and in their final days patients "do not feel hungry; food and drink may cause discomfort". The NCI explicitly warns: food and fluids should not be forced; this may cause discomfort or choking. The best things to offer are mouth care, small ice chips, and as much as the person wants, whenever they want it.
How many days can someone survive under rubble?
In an analysis of 34 earthquakes, the longest reliable report was 14 days, with the closest being 13 days. In 18 earthquakes with rescues after the second day, the mean maximum duration was 6.8 days. In the 1999 Marmara earthquake, documented rescue times ranged from 0.5 to 6.2 days. The "golden 72 hours" is a planning rule, not a biological limit.
What should be done first for someone being extracted from rubble?
Because of the risk of crush syndrome, particularly if the crushing has lasted more than four hours, intravenous fluids should be given before the limb is freed. As soon as pressure is released, potassium and myoglobin flood into the circulation; this can cause cardiac arrhythmia and kidney failure. Approximately half of patients with crush syndrome develop acute kidney failure.

Glossary

Dehydration
A reduction in body fluid sufficient to impair normal functioning.
Hypernatremia
An elevated blood sodium level; common in dehydration caused by water loss. Rapid correction may cause cerebral edema.
Ketosis
Ketone bodies becoming an energy source as fat breakdown increases during starvation.
Cachexia
A multifactorial syndrome involving skeletal muscle loss, not fully reversible by conventional nutritional support, leading to progressive functional impairment.
Sarcopenia
A reduction in muscle mass and strength.
Precachexia
The period of early metabolic changes before marked weight loss; the stage offering the greatest opportunity for intervention.
Refractory cachexia
Advanced cachexia unresponsive to treatment; life expectancy of less than three months.
Refeeding syndrome
Fluid and electrolyte shifts arising when a malnourished patient is rapidly refed; the characteristic finding is hypophosphatemia.
Thiamine (vitamin B1)
A vitamin involved in glucose metabolism. Its deficiency causes Wernicke-Korsakoff syndrome. It is not an electrolyte.
GDF-15
A protein secreted by some tumors that suppresses appetite centers in the brain. A new drug target in cachexia.
Ghrelin
A hormone secreted by the stomach that increases appetite. Anamorelin stimulates the receptor for this hormone.
Parenteral hydration
Giving fluids intravenously or subcutaneously, rather than orally.
Rhabdomyolysis
Breakdown of muscle tissue, releasing cellular contents into the circulation.
Myoglobinuria
Myoglobin released by muscle breakdown entering the urine; may cause renal tubular injury.
Compartment syndrome
Increased pressure within a muscle compartment that impedes circulation; may require fasciotomy.

Transparency note.

Verified: The durations for the ten people who died in the 1981 Maze Prison hunger strike and the 46–73-day range; the dates and duration of Angus Barbieri's fast, supplements taken, weights and publication details; the dates, location and duration of the Andreas Mihavecz case and his obtaining water from wall condensation; Poon Lim's ship, sinking and rescue dates, 133 days, the provisions on the raft and how he subsequently obtained food; the lack of scientific precision of the "rule of threes"; reports of a typical 10–14-day duration when both food and water are stopped in bedridden people; variation in body water proportions with age, sex and body composition; loss thresholds expressed relative to total body water and body weight, and the pediatric clinical classification; cerebral edema being a complication of rapid correction rather than a symptom of dehydration, and the 0.5 mOsm/L-per-hour rule; the dates, calorie levels, participant count and psychological findings of the Minnesota Starvation Experiment; the figures from the analysis of survival under rubble and the Marmara 1999 data; the components of crush syndrome, the 50% kidney failure rate, the 3–20% and 74% rates, and the "intravenous access before release" rule; the consensus definition, diagnostic criteria and three stages of cancer cachexia; the NCI's statements that increasing calories does not stop wasting; cachexia prevalence rates; data on the effects and risks of megestrol acetate; anamorelin's approval dates, indication and dose in Japan, and the EMA's refusal dates and reasons; the patient count, doses, outcomes and confidence intervals of the ponsegromab phase 2 trial; the mechanism of refeeding syndrome, hypophosphatemia as its characteristic finding, ASPEN's five-day window, and NICE's risk criteria and dose limits; the design, endpoints and outcomes of the Bruera randomized trial; NICE's two recommendations for the final days of life and its quality standard statement; family information statements from palliative care organizations and the NCI; the safety concern about foam-tipped oral swabs.

Not verified: Official confirmation of Mihavecz's Guinness entry; the total number taking part in the 1981 strike; Kevin Lynch's strike start date; percentages of rescues by day under rubble; numerical results of the ROMANA 1–2 trials; anamorelin's regulatory status in the USA; the magnitude and duration of corticosteroids' effect on appetite in cachexia (therefore not included in the text); the recommendations in the ESMO cachexia guideline (the page could not be accessed); cachexia percentages by tumor type; the exact publication year of the Bruera trial; a "warning signs" list for dehydration in cancer patients verified against a single authoritative source; the listing of mucositis, bowel obstruction and hypercalcemia as documented causes of dehydration; access to cachexia treatment, nutritional support and palliative care services in Turkey and the scope of SGK reimbursement — no claims have been made on these subjects.

Source of the criticisms: The assessments that "megestrol improves the wrong endpoint," "the ponsegromab data are promising but phase 2, 12-week and weight-based," "the golden 72 hours is not a biological limit" and "the tension between randomized evidence and guideline statements should not be turned into a one-sided recommendation" are those of this article. By contrast, cachexia not being reversible through nutrition, the EMA's reason for refusal, the Bruera trial's result and the NICE criteria are statements made by the cited sources themselves.

Disclosure of interests: We have no connection with any drug or manufacturer mentioned in this article.

References

  1. CAIN Archive, Ulster University. Chronology of the 1981 hunger strike. cain.ulster.ac.uk
  2. Stewart WK, Fleming LW. "Features of a successful therapeutic fast of 382 days' duration." Postgraduate Medical Journal, March 1973.
  3. Keys A, Brožek J, Henschel A, Mickelsen O, Taylor HL. The Biology of Human Starvation. University of Minnesota Press, 1950.
  4. Macintyre AG, Barbera JA, Smith ER. "Surviving collapsed structure entrapment after earthquakes: a 'time-to-rescue' analysis." Prehospital and Disaster Medicine, 2006.
  5. American College of Emergency Physicians / CDC. "Crush Injury and Crush Syndrome" blast injury fact sheet. acep.org
  6. Merck Manual Professional. "Hypernatremia" and "Dehydration in Children". merckmanuals.com
  7. U.S. Geological Survey. "Water in You: Water and the Human Body." usgs.gov
  8. Fearon K, Strasser F, Anker SD, et al. "Definition and classification of cancer cachexia: an international consensus." Lancet Oncology 2011. (Criteria are reported through NCI PDQ; the primary text could not be accessed.)
  9. National Cancer Institute. PDQ "Nutrition in Cancer Care" — Health Professional and Patient versions. cancer.gov
  10. Salacz M. "Megestrol Acetate for Cancer Anorexia-Cachexia." Palliative Care Network of Wisconsin, Fast Fact #100. mypcnow.org
  11. Ono Pharmaceutical. Adlumiz (anamorelin hydrochloride) market launch announcement, 21 April 2021. ono-pharma.com
  12. European Medicines Agency. Refusal of the anamorelin marketing authorization application (18 May 2017) and confirmation after reexamination (14 September 2017).
  13. Pfizer. "Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab." Press release, 14 September 2024. Simultaneous publication: New England Journal of Medicine, "Ponsegromab for the Treatment of Cancer Cachexia."
  14. StatPearls / NCBI Bookshelf. "Refeeding Syndrome." ncbi.nlm.nih.gov
  15. NICE Clinical Guideline CG32. Nutrition support for adults — refeeding risk criteria and dose recommendations. nice.org.uk
  16. Bruera E, et al. "Parenteral hydration in patients with advanced cancer: a multicenter, double-blind, placebo-controlled randomized trial." Journal of Clinical Oncology, DOI 10.1200/JCO.2012.44.6518.
  17. NICE NG31. "Care of dying adults in the last days of life." nice.org.uk
  18. NICE QS144. "Care of dying adults in the last days of life" — Quality statement 4: Hydration. nice.org.uk
  19. Marie Curie. "Eating and drinking when someone is dying" and "Hydration and nutrition" (for professionals). mariecurie.org.uk

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

How Long Can a Human Survive Without Food and Water?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy